Enanta to provide R&D and business update for 2020 at annual JPM conference

Enanta Pharmaceuticals (NASDAQ:ENTA) will provide an update on its R&D programs, introduce its newest program in human metapneumovirus (hMPV), as well as provide an update on its business outlook for 2020, during its presentation at the 38^th Annual J.P. Morgan Healthcare Conference on January 13, 2020.

The company expects to achieve the following milestones in calendar 2020:

Respiratory syncytial virus (RSV N) – Inhibitor EDP-938 and hMPV Inhibitor Leads.

Data from RSVP Phase 2b adult outpatient study in Q3.

Initiate Phase 2 dose ranging study in pediatric RSV patients and in adult transplant patients with RSV in Q4.

Perform optimization of Enanta’s current nanomolar hMPV inhibitor leads – HBV: Core Inhibitor EDP-514.­

Initiate Phase 1b in nuc-suppressed and viremic HBV patients in Q1 and Q2, respctively.

Non-alcoholic steatohepatitis (NASH) / primary biliary cholangitis (PBC): FXR Agonists EDP-305 and EDP-297

Initiate ARGON-2 Phase 2b study of EDP-305 in NASH by early Q2.­

Phase 2 data from INTREPID study of EDP-305 in PBC in 2Q. ­

Initiate Phase 1 study of EDP-297 (follow-on FXR) in mid-2020.

#JPM20

https://seekingalpha.com/news/3530671-enanta-to-provide-r-and-d-and-business-update-for-2020-during-annual-jpm-conference